GSK partner Hansoh posts late-stage trial win for lung cancer drug in China

Phase 3positivePositive

AI Analysis

Summary

GSK partner Hansoh reported a Phase 3 trial win for a lung cancer drug in China. The positive late-stage trial result represents a significant milestone for the development program.

Clinical Trial Data

Phase

Primary Endpoint

Met

Importance:7/10

Sentiment:

0.80

oncologylung cancerlate-stage trialchinapartnership

Related Companies

$GSK $HNPHY

Read the original article

Published by Seeking Alpha Healthcare on July 10, 2026 11:29 AM

Read Original